Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh, Alzheimer's Disease Research Center
mi
from
Pittsburgh, PA
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh, Alzheimer's Disease Research Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Roper St. Francis Hospital
mi
from
Charleston, SC
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Roper St. Francis Hospital
mi
from
Charleston, SC
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of British Columbia, Clinic for AD & Related Disorders
mi
from
Vancouver,
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of British Columbia, Clinic for AD & Related Disorders
mi
from
Vancouver,
Click here to add this to my saved trials
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Institute
mi
from
Phoenix, AZ
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly
Evaluation of a Patient-Centered Medication Therapy Management Intervention to Reduce Inappropriate Anticholinergic Prescribing in the Elderly
Status: Enrolling
Updated:  12/31/1969
Sander's BrownCenter on Aging
mi
from
Lexington, KY
A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly
Evaluation of a Patient-Centered Medication Therapy Management Intervention to Reduce Inappropriate Anticholinergic Prescribing in the Elderly
Status: Enrolling
Updated: 12/31/1969
Sander's BrownCenter on Aging
mi
from
Lexington, KY
Click here to add this to my saved trials
Care Ecosystem: Navigating Patients and Families Through Stages of Care
University of California, San Francisco (UCSF) and University of Nebraska Medical Center (UNMC) Care Ecosystem
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Care Ecosystem: Navigating Patients and Families Through Stages of Care
University of California, San Francisco (UCSF) and University of Nebraska Medical Center (UNMC) Care Ecosystem
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Care Ecosystem: Navigating Patients and Families Through Stages of Care
University of California, San Francisco (UCSF) and University of Nebraska Medical Center (UNMC) Care Ecosystem
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Care Ecosystem: Navigating Patients and Families Through Stages of Care
University of California, San Francisco (UCSF) and University of Nebraska Medical Center (UNMC) Care Ecosystem
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1
Status: Enrolling
Updated:  12/31/1969
University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II
mi
from
Los Angeles, CA
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1
Status: Enrolling
Updated: 12/31/1969
University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198
An Investigation of Retinal Findings in Patients With Signs and Symptoms of Alzheimer's Disease Enrolled in 09-M-0198
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198
An Investigation of Retinal Findings in Patients With Signs and Symptoms of Alzheimer's Disease Enrolled in 09-M-0198
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Parexel International; Harbor Hospital Center
mi
from
Baltimore, MD
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Parexel International; Harbor Hospital Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Universtiy; Radiology Dept
mi
from
Baltimore, MD
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Universtiy; Radiology Dept
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Territory Neurology & Research Institute
mi
from
Tucson, AZ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Territory Neurology & Research Institute
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Positron Research International
mi
from
Fremont, CA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Positron Research International
mi
from
Fremont, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Alliance Research Centers
mi
from
Laguna Hills, CA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Alliance Research Centers
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Senior Clinical Trials, Inc.
mi
from
Laguna Hills, CA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Senior Clinical Trials, Inc.
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Pacific Research Network
mi
from
San Diego, CA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Pacific Research Network
mi
from
San Diego, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
San Francisco Clinical Research Center
mi
from
San Francisco, CA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Mile High Research Center
mi
from
Denver, CO
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Mile High Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Direct Helpers Medical Center Inc
mi
from
Hialeah, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Direct Helpers Medical Center Inc
mi
from
Hialeah, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Berma Research
mi
from
Hialeah, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Berma Research
mi
from
Hialeah, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Galiz Research
mi
from
Hialeah, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Galiz Research
mi
from
Hialeah, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Maxblue Institute
mi
from
Hialeah, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Maxblue Institute
mi
from
Hialeah, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Advance Medical Research Institute
mi
from
Miami, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Advance Medical Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
New Horizon Research Center
mi
from
Miami, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
New Horizon Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
JDH Medical Group
mi
from
Miami, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
JDH Medical Group
mi
from
Miami, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
mi
from
Orlando, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Suncoast Neuroscience Associates Inc
mi
from
Saint Petersburg, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Suncoast Neuroscience Associates Inc
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Roskamp Institute
mi
from
Sarasota, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Roskamp Institute
mi
from
Sarasota, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Stedman Clinical Trials
mi
from
Tampa, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Premiere Research Institute at Palm Beach Neurology
mi
from
West Palm Beach, FL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Premiere Research Institute at Palm Beach Neurology
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
The Multiple Sclerosis Center of Atlanta
mi
from
Atlanta, GA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
The Multiple Sclerosis Center of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Medical Center
mi
from
Elk Grove Village, IL
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Medical Center
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
ActivMed Practices & Research
mi
from
Methuen, MA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
ActivMed Practices & Research
mi
from
Methuen, MA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Boston Center for Memory
mi
from
Newton, MA
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Boston Center for Memory
mi
from
Newton, MA
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Hattiesburg Clinic
mi
from
Hattiesburg, MS
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Hattiesburg Clinic
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
The Cognitive and Research Center of NJ
mi
from
Springfield, NJ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
The Cognitive and Research Center of NJ
mi
from
Springfield, NJ
Click here to add this to my saved trials
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated:  12/31/1969
Advanced Memory Research Institute of New Jersey
mi
from
Toms River, NJ
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Status: Enrolling
Updated: 12/31/1969
Advanced Memory Research Institute of New Jersey
mi
from
Toms River, NJ
Click here to add this to my saved trials